18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other molecule...
19:03 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture studies suggest inhibiting PDE3A, FYB1, BICC1 or PURPL could help treat liver cancer. In two human liver cancer cell lines, shRNA targeting PDE3A, FYB1, BICC1 or PURPL decreased viability and colony...
20:42 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 30 genomic loci could help predict the risk of schizophrenia. Genome-wide association studies in 47,559 schizophrenia patients and 70,936 healthy volunteers identified associations between the disease and SNPs on 30 loci, including...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: FYN proto-oncogene src family tyrosine kinase (FYN)

Cardiovascular disease INDICATION: Heart failure Patient sample and mouse studies suggest promoting cardiomyocyte expression of FYN could help treat heart failure. In cardiomyocytes from heart failure patients, FYN levels were lower than in cardiomyocytes from healthy volunteers....
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: FYN proto-oncogene src family tyrosine kinase (FYN); protein kinase C (PKC) δ (PRKCD)

Neurology INDICATION: Neurology In vitro and mouse studies suggest inhibiting FYN or PKCδ could help treat neuroinflammatory diseases such as Parkinson's disease (PD). In mouse microglia, lipopolysaccharide (LPS)-induced inflammation increased FYN activation, phosphorylation of the downstream protein...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Covagen, J&J deal

Johnson & Johnson’s Cilag GmbH International subsidiary acquired mAb platform company Covagen for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which fuses antibodies to Fynomers. Fynomers are...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Exiting Covagen

Terms of Johnson & Johnson's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size and...
00:36 , Aug 26, 2014 |  BC Extra  |  Company News

J&J acquires antibody play Covagen

The Cilag GmbH International subsidiary of Johnson & Johnson (NYSE:JNJ) acquired mAb platform company Covagen AG (Zurich, Switzerland) for an undisclosed amount. Covagen is developing a pipeline of products using its FynomAb engineering technology, which...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

COVA322: Phase Ib/IIa started

Covagen began a double-blind, placebo-controlled, German Phase Ib/IIa trial to evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's Fynomer protein engineering technology. Fynomers are based on the...
01:29 , Dec 10, 2013 |  BC Extra  |  Financial News

Covagen secures $47.1 million in series B

Covagen AG (Zurich, Switzerland) secured CHF42 million ($47.1 million) in a tranched series B round led by new investor Gimv. New investor Ascent Biomedical Ventures also participated, along with existing investors Novartis Venture Fund; Edmond...